L. Verlingue

发表

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

N. Paragios, J. Soria, J. Scoazec, 2018, The Lancet. Oncology.

Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.

X. Paoletti, N. Servant, J. Pierga, 2014, Personalized medicine.

Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.

A. Geraud, J. Soria, J. Armand, 2022, European journal of cancer.

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.

V. Boige, A. Hollebecque, D. Malka, 2017, Seminars in oncology.

Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials.

J. Soria, L. Lacroix, A. Hollebecque, 2022, European journal of cancer.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

D. Schadendorf, P. Opolon, G. Madonna, 2019, Cell Research.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

T. de Baère, M. Ducreux, S. Michiels, 2017, European journal of cancer.

Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center.

J. Soria, F. Scotté, V. Ribrag, 2021, Journal of Clinical Oncology.

Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers.

B. Besse, A. Hollebecque, D. Morel, 2022, Cancer Treatment and Research Communications.

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer

D. Gautheret, Ismael Padioleau, P. Cournède, 2022, medRxiv.

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.

D. Planchard, A. Italiano, J. Soria, 2022, JCO precision oncology.

Applications of single-cell and bulk RNA sequencing in onco-immunology.

Daniel Gautheret, Andrei Zinovyev, Maria Kuksin, 2021, European journal of cancer.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

D. Schadendorf, P. Opolon, G. Madonna, 2019, Cell Research.

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

N. Chaput, A. Leary, E. Despras, 2017, European journal of cancer.

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

S. Broutin, J. Delahousse, A. Paci, 2018, European journal of cancer.

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

M. Ducreux, V. Boige, C. Ferté, 2017, European journal of cancer.

Molecular analysis for refractory rare cancers: sequencing battle continues: learnings for the MOSCATO-01 study.

S. Michiels, G. Malouf, A. Hollebecque, 2022, Critical reviews in oncology/hematology.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Marie-Cécile Le Deley, Stefan Michiels, Caroline Even, 2017, Cancer discovery.

A comprehensive approach to the molecular determinants of lifespan using a Boolean model of geroconversion

Emmanuel Barillot, Laurence Calzone, Gautier Stoll, 2016, Aging cell.

Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers

M. Ducreux, V. Boige, A. Hollebecque, 2021, Expert opinion on investigational drugs.

Denoised VEGFR2 expression relates to sunitinib efficacy in advanced Clear Cell Renal Cell Carcinoma

J. Bernhard, J. Schmidt, D. Morel, 2021, medRxiv.

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

R. Dziadziuszko, A. Italiano, S. Evers, 2021 .

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

J. Koivunen, M. D. de Jonge, M. Karvonen, 2021, Annals of Oncology.

PALLIA 10 score in phase I cancer studies

J. Soria, F. Scotté, V. Ribrag, 2022, BMJ supportive & palliative care.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

E. Solary, O. Mir, T. de Baère, 2018, European journal of cancer.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

E. Solary, T. de Baère, S. Michiels, 2018, Oncotarget.

Natural language processing for patient selection in phase I/II oncology clinical trials

J. Soria, S. Mercier, B. Besse, 2021, medRxiv.

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2.

A. Hollebecque, L. Verlingue, C. Massard, 2019, JCO clinical cancer informatics.

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic

S. Michiels, J. Soria, F. Barlesi, 2021, Cancer Cell.

The spectrum of clinical trials aiming at personalizing medicine.

V. Servois, X. Paoletti, N. Servant, 2014, Chinese clinical oncology.

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

P. Jaakkola, M. Karvonen, S. Iivanainen, 2023, medRxiv.

Abstract PR009: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

D. Gautheret, P. Cournède, S. Michiels, 2023, Cancer Research.

DeepOS: pan-cancer prognosis estimation from RNA-sequencing data

S. Christodoulidis, H. Vanacker, D. Morel, 2021, medRxiv.

Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.).

S. Koscielny, C. Ferté, L. Verlingue, 2014, European journal of cancer.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

N. Paragios, J. Soria, J. Scoazec, 2018, The Lancet. Oncology.

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer

D. Gautheret, P. Cournède, Y. Loriot, 2023, Cancer discovery.

[The breakthrough of personalized medicine, new hopes and new challenges].

A. Schernberg, R. Flippot, L. Verlingue, 2017, Bulletin du cancer.

BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.

J. Shih, A. Italiano, C. Basson, 2021 .

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).

C. Neuzillet, L. Verlingue, O. Rosmorduc, 2024, European journal of cancer.